Wall Street brokerages expect that Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) will post ($0.17) earnings per share for the current fiscal quarter, according to Zacks Investment Research. Two analysts have issued estimates for Lexicon Pharmaceuticals’ earnings, with the lowest EPS estimate coming in at ($0.25) and the highest estimate coming in at ($0.12). Lexicon Pharmaceuticals posted earnings of ($0.63) per share in the same quarter last year, which would suggest a positive year over year growth rate of 73%. The business is scheduled to issue its next quarterly earnings report after the market closes on Thursday, May 6th.
According to Zacks, analysts expect that Lexicon Pharmaceuticals will report full year earnings of ($0.27) per share for the current fiscal year, with EPS estimates ranging from ($0.65) to $0.76. For the next financial year, analysts forecast that the business will report earnings of ($0.40) per share, with EPS estimates ranging from ($0.55) to ($0.20). Zacks’ earnings per share averages are an average based on a survey of research analysts that cover Lexicon Pharmaceuticals.
Lexicon Pharmaceuticals (NASDAQ:LXRX) last posted its earnings results on Wednesday, March 10th. The biopharmaceutical company reported ($0.05) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.28) by $0.23. Lexicon Pharmaceuticals had a negative net margin of 320.44% and a negative return on equity of 164.96%. The company had revenue of $0.20 million during the quarter, compared to analyst estimates of $0.17 million.
In related news, VP James F. Tessmer sold 22,912 shares of Lexicon Pharmaceuticals stock in a transaction dated Monday, March 15th. The shares were sold at an average price of $6.92, for a total transaction of $158,551.04. Following the completion of the transaction, the vice president now directly owns 71,766 shares of the company’s stock, valued at approximately $496,620.72. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. 6.40% of the stock is currently owned by insiders.
A number of institutional investors have recently added to or reduced their stakes in LXRX. Steel Peak Wealth Management LLC purchased a new stake in Lexicon Pharmaceuticals in the 4th quarter valued at about $34,000. Victory Capital Management Inc. purchased a new stake in Lexicon Pharmaceuticals in the 4th quarter valued at about $42,000. XTX Markets LLC purchased a new stake in Lexicon Pharmaceuticals in the 4th quarter valued at about $45,000. Aperio Group LLC purchased a new stake in Lexicon Pharmaceuticals in the 4th quarter valued at about $50,000. Finally, Dimensional Fund Advisors LP purchased a new stake in Lexicon Pharmaceuticals in the 4th quarter valued at about $57,000. 84.62% of the stock is owned by institutional investors.
LXRX stock traded down $0.31 on Tuesday, hitting $4.53. The company had a trading volume of 63,429 shares, compared to its average volume of 3,915,176. Lexicon Pharmaceuticals has a 12-month low of $1.03 and a 12-month high of $9.65. The company has a current ratio of 1.54, a quick ratio of 1.55 and a debt-to-equity ratio of 0.13. The stock’s 50-day simple moving average is $5.62 and its 200 day simple moving average is $4.71. The stock has a market cap of $653.92 million, a price-to-earnings ratio of -4.31 and a beta of 2.09.
About Lexicon Pharmaceuticals
Lexicon Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; LX9211, which is in Phase II clinical development for the treatment of neuropathic pain; and LX2761.
Featured Article: What is required to own or exchange cryptocurrency?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Lexicon Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lexicon Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.